Aug 20, 2026 – 12.14pmBoston-headquartered buyout player Advent International is expanding its eclectic portfolio across the Pacific Ocean.Street Talk can reveal Advent, led locally by former Anchorage Capital Partners dealmaker Beau Dixon, has agreed terms to acquire a significant stake in New Zealand Clinical Research (NZCR).Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones.Kanika Sood is a journalist based in Sydney who writes for the Street Talk column.Angira Bharadwaj is a co-editor of Street Talk. She covers IPOs, capital raises, mergers and acquisitions and other breaking news in Australia’s capital markets. Previously, she covered financial services, state, and federal politics. Send tips to @angirab.60 on encrypted messaging platform Signal.Subscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber?
Advent International buys $1b stake in Kiwi clinical trials giant NZCR
The deal will see Advent buy a significant stake, investing alongside Waterman Capital and NZCR’s doctors.
158 words~1 min read
